scispace - formally typeset
Search or ask a question
Author

Arnon Nagler

Bio: Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.


Papers
More filters
Journal ArticleDOI
01 Feb 1998-Blood
TL;DR: Preliminary data in 26 patients with standard indications for allogeneic BMT suggest that nonmyeloablative conditioning including fludarabine, anti-T-lymphocyte globulin, and low-dose busulfan is extremely well tolerated, with no severe procedure-related toxicity.

2,079 citations

Journal ArticleDOI
01 Jun 2000-Blood
TL;DR: It is demonstrated that repopulating human stem cells functionally express LFA-1, VLA-4, andVLA-5, and this study implies a novel approach to further advance clinical transplantation.

748 citations

Journal ArticleDOI
TL;DR: PLD with bortzomib is superior to bortezomib monotherapy for the treatment of patients with relapsed or refractory multiple myeloma, and the combination therapy is associated with a higher incidence of grade 3/4 myelosuppression, constitutional symptoms, and GI and dermatologic toxicities.
Abstract: Purpose This phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy in patients with relapsed or refractory multiple myeloma. Patients and Methods Six hundred forty-six patients were randomly assigned to receive either intravenous bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of an every 21-days cycle, or the same bortezomib regimen with PLD 30 mg/m2 on day 4. Results Median time to progression was increased from 6.5 months for bortezomib to 9.3 months with the PLD + bortezomib combination (P = .000004; hazard ratio, 1.82 [monotherapy v combination therapy]; 95% CI, 1.41 to 2.35). The 15-month survival rate for PLD + bortezomib was 76% compared with 65% for bortezomib alone (P = .03). The complete plus partial response rate was 41% for bortezomib and 44% for PLD + bortezomib, a difference that was not statistically significant. Median duration of response was increased from 7.0 to 10.2 months (P = ...

596 citations

Journal ArticleDOI
Camille N. Abboud, Ellin Berman, Adam D. Cohen, Jorge E. Cortes, Daniel J. DeAngelo, Michael W. Deininger, Steven M. Devine, Brian J. Druker, Amir T. Fathi, Elias Jabbour, Madan Jagasia, Hagop M. Kantarjian, Jean Khoury, Pierre Laneuville, Richard A. Larson, Jeffrey H. Lipton, Joseph O. Moore, Tariq I. Mughal, Susan O'Brien, Javier Pinilla-Ibarz, Alfonso Quintás-Cardama, Jerald P. Radich, Vishnu Reddy, Charles A. Schiffer, Neil P. Shah, Paul J. Shami, Richard T. Silver, David S. Snyder, Richard Stone, Moshe Talpaz, Ayalew Tefferi, Richard A. Van Etten, Meir Wetzler, Elisabetta Abruzzese, Jane F. Apperley, Massimo Breccia, Jenny Byrne, Francisco Cervantes, Ekaterina Chelysheva, Richard E. Clark, Hugues de Lavallade, Iryna Dyagil, Carlo Gambacorti-Passerini, John M. Goldman, Ibrahim C. Haznedaroglu, Henrik Hjorth-Hansen, Tessa L. Holyoake, Brian J. P. Huntly, Philipp le Coutre, Elza Lomaia, Francois-Xavier Mahon, David Marin-Costa, Giovanni Martinelli, Jiri Mayer, Dragana Milojkovic, Eduardo Olavarria, Kimmo Porkka, Johan Richter, Philippe Rousselot, Giuseppe Saglio, Güray Saydam, Jesper Stentoft, Anna G. Turkina, Paolo Vigneri, Andrey Zaritskey, Alvaro Aguayo, Manuel Ayala, Israel Bendit, Raquel Bengió, Carlos Best, Eduardo Bullorsky, Eduardo Cervera, Carmino DeSouza, Ernesto Fanilla, David Gómez-Almaguer, Nelson Hamerschlak, José A. López, Alicia Magarinos, Luis Meillon, Jorge Milone, Beatriz Moiraghi, Ricardo Pasquini, Carolina Pavlovsky, Guillermo J. Ruiz-Argüelles, Nelson Spector, Christopher Arthur, Peter Browett, Andrew Grigg, Jianda Hu, Xiao-Jun Huang, Timothy P. Hughes, Qian Jiang, Saengsuree Jootar, Dong-Wook Kim, Hemant Malhotra, Pankaj Malhotra, Itaru Matsumura, Junia V. Melo, Kazunori Ohnishi, Ryuzo Ohno, Tapan Saikia, Anthony P. Schwarer, Naoto Takahashi, Constantine S. Tam, Tetsuzo Tauchi, Kensuke Usuki, Jianxiang Wang, Fawzi Abdel-Rahman, Mahmoud Aljurf, Ali Bazarbachi, Dina Ben Yehuda, Naeem Chaudhri, Muheez A. Durosinmi, Hossam Kamel, Vernon J. Louw, Bassam Francis Matti, Arnon Nagler, Pia Raanani, Ziad Salem 
30 May 2013-Blood
TL;DR: There is a need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.

558 citations

Journal ArticleDOI
TL;DR: The results confirm that the clinical benefit of donor lymphocyte infusion in the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation (HSCT) is limited to a minority of patients.
Abstract: Purpose To evaluate the role of donor lymphocyte infusion (DLI) in the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). Patients and Methods We retrospectively analyzed the data of 399 patients with AML in first hematological relapse after HSCT whose treatment did (n = 171) or did not (n = 228) include DLI. After correction for imbalances and established risk factors, the two groups were compared with respect to overall survival. Further, a detailed analysis of risk factors for survival among DLI recipients was performed. Results Median follow-up was 27 and 40 months, respectively. Estimated survival at 2 years (± standard deviation) was 21% ± 3% for patients receiving DLI and 9% ± 2% for patients not receiving DLI. After adjustment for differences between the groups, better outcome was associated with age younger than 37 years (P = .008), relapse occurring more than 5 months after HSCT (P < .0001), and use of DLI (P = .04). Among DLI reci...

426 citations


Cited by
More filters
Journal ArticleDOI

[...]

08 Dec 2001-BMJ
TL;DR: There is, I think, something ethereal about i —the square root of minus one, which seems an odd beast at that time—an intruder hovering on the edge of reality.
Abstract: There is, I think, something ethereal about i —the square root of minus one. I remember first hearing about it at school. It seemed an odd beast at that time—an intruder hovering on the edge of reality. Usually familiarity dulls this sense of the bizarre, but in the case of i it was the reverse: over the years the sense of its surreal nature intensified. It seemed that it was impossible to write mathematics that described the real world in …

33,785 citations

Book
29 Sep 2017
TL;DR: Thank you very much for reading who classification of tumours of haematopoietic and lymphoid tissues, and maybe you have knowledge that, people have look hundreds of times for their chosen readings like this, but end up in malicious downloads.
Abstract: WHO CLASSIFICATION OF TUMOURS OF HAEMATOPOIETIC AND LYMPHOID TISSUES , WHO CLASSIFICATION OF TUMOURS OF HAEMATOPOIETIC AND LYMPHOID TISSUES , کتابخانه مرکزی دانشگاه علوم پزشکی تهران

13,835 citations

Journal ArticleDOI
TL;DR: It is shown that the MMPs have functions other than promotion of invasion, have substrates other than components of the extracellular matrix, and that they function before invasion in the development of cancer.
Abstract: Matrix metalloproteinases (MMPs) have long been associated with cancer-cell invasion and metastasis. This provided the rationale for clinical trials of MMP inhibitors, unfortunately with disappointing results. We now know, however, that the MMPs have functions other than promotion of invasion, have substrates other than components of the extracellular matrix, and that they function before invasion in the development of cancer. With this knowledge in hand, can we rethink the use of MMP inhibitors in the clinic?

5,860 citations

01 Jan 2020
TL;DR: Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Abstract: Summary Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.

4,408 citations